SEI Medical Public Company Limited (SEI), a medical and scientific equipment distributor business, is ready to list on the Market for Alternative Investment (mai) on 24 September, with a market capitalization at the IPO price of 527 million baht, using the abbreviation 'SEI.'

Mr. Prapan Charoenprasert, Manager of the Market for Alternative Investment (mai), revealed that the mai welcomes SEI Medical Public Company Limited to list and start trading on mai under the Consumer Products industry group, using the abbreviation 'SEI' on 24 September 2024.

SEI primarily operates as a distributor and service provider of medical equipment. The company sources medical and scientific equipment from 18 leading overseas manufacturers from 11 countries. The products can be categorized into 5 groups: endoscopes, products for newborns, beauty, surgery, and scientific equipment and devices. The company's target customers include government hospitals, medical education institutions, private hospitals, and clinics. In the first half of 2024, the company had revenue from sales of Services and others in the proportion of 90:10 respectively, with revenue from sales and services from government customers accounting for 79 percent of total revenue from sales and services, and the main product groups including: The group of products is Endoscope 52 percent, the group of products for newborn patients 42 percent, and the group of products is Other 6 percent.

SEI has a paid-up capital after the offering of 85 million baht, with a par value of 0.50 baht per share, consisting of 120 million existing ordinary shares and 50 million newly issued ordinary shares, of which 37.50 million shares will be offered to persons at the discretion of the underwriter, 7.50 million shares will be offered to the company's benefactors, and 5.00 million shares will be offered to directors, executives, and employees on September 16-18, 2024 at a price of 3.10 baht per share, for an IPO offering value of 155 million baht, with a securities value at the IPO price of 527 million baht. The IPO offering price is determined by considering the price-to-earnings ratio (P/E Ratio) of 19.64 times, calculated from net profit for the past 12 months (from July 1, 2023 to June 30, 2024). 2567) divided by the number of common shares issued and paid after the offering of shares this time (fully diluted), resulting in net profit per share equal to 0.16 baht, with Avantgarde Capital Co., Ltd. as financia l advisor and Yuanta Securities (Thailand) Co., Ltd. as underwriter and underwriter.

Mr. Kan Punyacharoensin, Chief Executive Officer of SEI Medical Public Company Limited, revealed that throughout the more than 30 years in the medical and scientific equipment industry, the company has focused on improving the quality of life and health of the population through innovation and cutting-edge technology. The funds raised from the fundraising will be used as working capital to expand the business, including increasing potential and competitiveness, such as working capital to purchase medical equipment and devices, to expand the consumables business, and joint investment projects with other companies engaged in the medical business, which may include specialized clinics or hospitals.

SEI has major shareholders after the IPO, namely Mr. Thira Punyacharoensin, holding 35.29 percent of shares, and Mr. Kan Punyacharoensin, holding 31.76 percent of shares. The company has a policy to pay dividends to shareholders at a rate of not less than 40 percent of net profit after tax and legal reserves.

Source: Thai News Agency

SEI Medical Public Company Limited (SEI), a medical and scientific equipment distributor business, is ready to list on the Market for Alternative Investment (mai) on 24 September, with a market capitalization at the IPO price of 527 million baht, using the abbreviation 'SEI.'

Mr. Prapan Charoenprasert, Manager of the Market for Alternative Investment (mai), revealed that the mai welcomes SEI Medical Public Company Limited to list and start trading on mai under the Consumer Products industry group, using the abbreviation 'SEI' on 24 September 2024.

SEI primarily operates as a distributor and service provider of medical equipment. The company sources medical and scientific equipment from 18 leading overseas manufacturers from 11 countries. The products can be categorized into 5 groups: endoscopes, products for newborns, beauty, surgery, and scientific equipment and devices. The company's target customers include government hospitals, medical education institutions, private hospitals, and clinics. In the first half of 2024, the company had revenue from sales of Services and others in the proportion of 90:10 respectively, with revenue from sales and services from government customers accounting for 79 percent of total revenue from sales and services, and the main product groups including: The group of products is Endoscope 52 percent, the group of products for newborn patients 42 percent, and the group of products is Other 6 percent.

SEI has a paid-up capital after the offering of 85 million baht, with a par value of 0.50 baht per share, consisting of 120 million existing ordinary shares and 50 million newly issued ordinary shares, of which 37.50 million shares will be offered to persons at the discretion of the underwriter, 7.50 million shares will be offered to the company's benefactors, and 5.00 million shares will be offered to directors, executives, and employees on September 16-18, 2024 at a price of 3.10 baht per share, for an IPO offering value of 155 million baht, with a securities value at the IPO price of 527 million baht. The IPO offering price is determined by considering the price-to-earnings ratio (P/E Ratio) of 19.64 times, calculated from net profit for the past 12 months (from July 1, 2023 to June 30, 2024). 2567) divided by the number of common shares issued and paid after the offering of shares this time (fully diluted), resulting in net profit per share equal to 0.16 baht, with Avantgarde Capital Co., Ltd. as financia l advisor and Yuanta Securities (Thailand) Co., Ltd. as underwriter and underwriter.

Mr. Kan Punyacharoensin, Chief Executive Officer of SEI Medical Public Company Limited, revealed that throughout the more than 30 years in the medical and scientific equipment industry, the company has focused on improving the quality of life and health of the population through innovation and cutting-edge technology. The funds raised from the fundraising will be used as working capital to expand the business, including increasing potential and competitiveness, such as working capital to purchase medical equipment and devices, to expand the consumables business, and joint investment projects with other companies engaged in the medical business, which may include specialized clinics or hospitals.

SEI has major shareholders after the IPO, namely Mr. Thira Punyacharoensin, holding 35.29 percent of shares, and Mr. Kan Punyacharoensin, holding 31.76 percent of shares. The company has a policy to pay dividends to shareholders at a rate of not less than 40 percent of net profit after tax and legal reserves.

Source: Thai News Agency

SEI Medical Public Company Limited (SEI), a medical and scientific equipment distributor business, is ready to list on the Market for Alternative Investment (mai) on 24 September, with a market capitalization at the IPO price of 527 million baht, using the abbreviation 'SEI.'

Mr. Prapan Charoenprasert, Manager of the Market for Alternative Investment (mai), revealed that the mai welcomes SEI Medical Public Company Limited to list and start trading on mai under the Consumer Products industry group, using the abbreviation 'SEI' on 24 September 2024.

SEI primarily operates as a distributor and service provider of medical equipment. The company sources medical and scientific equipment from 18 leading overseas manufacturers from 11 countries. The products can be categorized into 5 groups: endoscopes, products for newborns, beauty, surgery, and scientific equipment and devices. The company's target customers include government hospitals, medical education institutions, private hospitals, and clinics. In the first half of 2024, the company had revenue from sales of Services and others in the proportion of 90:10 respectively, with revenue from sales and services from government customers accounting for 79 percent of total revenue from sales and services, and the main product groups including: The group of products is Endoscope 52 percent, the group of products for newborn patients 42 percent, and the group of products is Other 6 percent.

SEI has a paid-up capital after the offering of 85 million baht, with a par value of 0.50 baht per share, consisting of 120 million existing ordinary shares and 50 million newly issued ordinary shares, of which 37.50 million shares will be offered to persons at the discretion of the underwriter, 7.50 million shares will be offered to the company's benefactors, and 5.00 million shares will be offered to directors, executives, and employees on September 16-18, 2024 at a price of 3.10 baht per share, for an IPO offering value of 155 million baht, with a securities value at the IPO price of 527 million baht. The IPO offering price is determined by considering the price-to-earnings ratio (P/E Ratio) of 19.64 times, calculated from net profit for the past 12 months (from July 1, 2023 to June 30, 2024). 2567) divided by the number of common shares issued and paid after the offering of shares this time (fully diluted), resulting in net profit per share equal to 0.16 baht, with Avantgarde Capital Co., Ltd. as financia l advisor and Yuanta Securities (Thailand) Co., Ltd. as underwriter and underwriter.

Mr. Kan Punyacharoensin, Chief Executive Officer of SEI Medical Public Company Limited, revealed that throughout the more than 30 years in the medical and scientific equipment industry, the company has focused on improving the quality of life and health of the population through innovation and cutting-edge technology. The funds raised from the fundraising will be used as working capital to expand the business, including increasing potential and competitiveness, such as working capital to purchase medical equipment and devices, to expand the consumables business, and joint investment projects with other companies engaged in the medical business, which may include specialized clinics or hospitals.

SEI has major shareholders after the IPO, namely Mr. Thira Punyacharoensin, holding 35.29 percent of shares, and Mr. Kan Punyacharoensin, holding 31.76 percent of shares. The company has a policy to pay dividends to shareholders at a rate of not less than 40 percent of net profit after tax and legal reserves.

Source: Thai News Agency

SEI Medical Public Company Limited (SEI), a medical and scientific equipment distributor business, is ready to list on the Market for Alternative Investment (mai) on 24 September, with a market capitalization at the IPO price of 527 million baht, using the abbreviation 'SEI.'

Mr. Prapan Charoenprasert, Manager of the Market for Alternative Investment (mai), revealed that the mai welcomes SEI Medical Public Company Limited to list and start trading on mai under the Consumer Products industry group, using the abbreviation 'SEI' on 24 September 2024.

SEI primarily operates as a distributor and service provider of medical equipment. The company sources medical and scientific equipment from 18 leading overseas manufacturers from 11 countries. The products can be categorized into 5 groups: endoscopes, products for newborns, beauty, surgery, and scientific equipment and devices. The company's target customers include government hospitals, medical education institutions, private hospitals, and clinics. In the first half of 2024, the company had revenue from sales of Services and others in the proportion of 90:10 respectively, with revenue from sales and services from government customers accounting for 79 percent of total revenue from sales and services, and the main product groups including: The group of products is Endoscope 52 percent, the group of products for newborn patients 42 percent, and the group of products is Other 6 percent.

SEI has a paid-up capital after the offering of 85 million baht, with a par value of 0.50 baht per share, consisting of 120 million existing ordinary shares and 50 million newly issued ordinary shares, of which 37.50 million shares will be offered to persons at the discretion of the underwriter, 7.50 million shares will be offered to the company's benefactors, and 5.00 million shares will be offered to directors, executives, and employees on September 16-18, 2024 at a price of 3.10 baht per share, for an IPO offering value of 155 million baht, with a securities value at the IPO price of 527 million baht. The IPO offering price is determined by considering the price-to-earnings ratio (P/E Ratio) of 19.64 times, calculated from net profit for the past 12 months (from July 1, 2023 to June 30, 2024). 2567) divided by the number of common shares issued and paid after the offering of shares this time (fully diluted), resulting in net profit per share equal to 0.16 baht, with Avantgarde Capital Co., Ltd. as financia l advisor and Yuanta Securities (Thailand) Co., Ltd. as underwriter and underwriter.

Mr. Kan Punyacharoensin, Chief Executive Officer of SEI Medical Public Company Limited, revealed that throughout the more than 30 years in the medical and scientific equipment industry, the company has focused on improving the quality of life and health of the population through innovation and cutting-edge technology. The funds raised from the fundraising will be used as working capital to expand the business, including increasing potential and competitiveness, such as working capital to purchase medical equipment and devices, to expand the consumables business, and joint investment projects with other companies engaged in the medical business, which may include specialized clinics or hospitals.

SEI has major shareholders after the IPO, namely Mr. Thira Punyacharoensin, holding 35.29 percent of shares, and Mr. Kan Punyacharoensin, holding 31.76 percent of shares. The company has a policy to pay dividends to shareholders at a rate of not less than 40 percent of net profit after tax and legal reserves.

Source: Thai News Agency

SEI Medical Public Company Limited (SEI), a medical and scientific equipment distributor business, is ready to list on the Market for Alternative Investment (mai) on 24 September, with a market capitalization at the IPO price of 527 million baht, using the abbreviation 'SEI.'

Mr. Prapan Charoenprasert, Manager of the Market for Alternative Investment (mai), revealed that the mai welcomes SEI Medical Public Company Limited to list and start trading on mai under the Consumer Products industry group, using the abbreviation 'SEI' on 24 September 2024.

SEI primarily operates as a distributor and service provider of medical equipment. The company sources medical and scientific equipment from 18 leading overseas manufacturers from 11 countries. The products can be categorized into 5 groups: endoscopes, products for newborns, beauty, surgery, and scientific equipment and devices. The company's target customers include government hospitals, medical education institutions, private hospitals, and clinics. In the first half of 2024, the company had revenue from sales of Services and others in the proportion of 90:10 respectively, with revenue from sales and services from government customers accounting for 79 percent of total revenue from sales and services, and the main product groups including: The group of products is Endoscope 52 percent, the group of products for newborn patients 42 percent, and the group of products is Other 6 percent.

SEI has a paid-up capital after the offering of 85 million baht, with a par value of 0.50 baht per share, consisting of 120 million existing ordinary shares and 50 million newly issued ordinary shares, of which 37.50 million shares will be offered to persons at the discretion of the underwriter, 7.50 million shares will be offered to the company's benefactors, and 5.00 million shares will be offered to directors, executives, and employees on September 16-18, 2024 at a price of 3.10 baht per share, for an IPO offering value of 155 million baht, with a securities value at the IPO price of 527 million baht. The IPO offering price is determined by considering the price-to-earnings ratio (P/E Ratio) of 19.64 times, calculated from net profit for the past 12 months (from July 1, 2023 to June 30, 2024). 2567) divided by the number of common shares issued and paid after the offering of shares this time (fully diluted), resulting in net profit per share equal to 0.16 baht, with Avantgarde Capital Co., Ltd. as financia l advisor and Yuanta Securities (Thailand) Co., Ltd. as underwriter and underwriter.

Mr. Kan Punyacharoensin, Chief Executive Officer of SEI Medical Public Company Limited, revealed that throughout the more than 30 years in the medical and scientific equipment industry, the company has focused on improving the quality of life and health of the population through innovation and cutting-edge technology. The funds raised from the fundraising will be used as working capital to expand the business, including increasing potential and competitiveness, such as working capital to purchase medical equipment and devices, to expand the consumables business, and joint investment projects with other companies engaged in the medical business, which may include specialized clinics or hospitals.

SEI has major shareholders after the IPO, namely Mr. Thira Punyacharoensin, holding 35.29 percent of shares, and Mr. Kan Punyacharoensin, holding 31.76 percent of shares. The company has a policy to pay dividends to shareholders at a rate of not less than 40 percent of net profit after tax and legal reserves.

Source: Thai News Agency

SEI Medical Public Company Limited (SEI), a medical and scientific equipment distributor business, is ready to list on the Market for Alternative Investment (mai) on 24 September, with a market capitalization at the IPO price of 527 million baht, using the abbreviation 'SEI.'

Mr. Prapan Charoenprasert, Manager of the Market for Alternative Investment (mai), revealed that the mai welcomes SEI Medical Public Company Limited to list and start trading on mai under the Consumer Products industry group, using the abbreviation 'SEI' on 24 September 2024.

SEI primarily operates as a distributor and service provider of medical equipment. The company sources medical and scientific equipment from 18 leading overseas manufacturers from 11 countries. The products can be categorized into 5 groups: endoscopes, products for newborns, beauty, surgery, and scientific equipment and devices. The company's target customers include government hospitals, medical education institutions, private hospitals, and clinics. In the first half of 2024, the company had revenue from sales of Services and others in the proportion of 90:10 respectively, with revenue from sales and services from government customers accounting for 79 percent of total revenue from sales and services, and the main product groups including: The group of products is Endoscope 52 percent, the group of products for newborn patients 42 percent, and the group of products is Other 6 percent.

SEI has a paid-up capital after the offering of 85 million baht, with a par value of 0.50 baht per share, consisting of 120 million existing ordinary shares and 50 million newly issued ordinary shares, of which 37.50 million shares will be offered to persons at the discretion of the underwriter, 7.50 million shares will be offered to the company's benefactors, and 5.00 million shares will be offered to directors, executives, and employees on September 16-18, 2024 at a price of 3.10 baht per share, for an IPO offering value of 155 million baht, with a securities value at the IPO price of 527 million baht. The IPO offering price is determined by considering the price-to-earnings ratio (P/E Ratio) of 19.64 times, calculated from net profit for the past 12 months (from July 1, 2023 to June 30, 2024). 2567) divided by the number of common shares issued and paid after the offering of shares this time (fully diluted), resulting in net profit per share equal to 0.16 baht, with Avantgarde Capital Co., Ltd. as financia l advisor and Yuanta Securities (Thailand) Co., Ltd. as underwriter and underwriter.

Mr. Kan Punyacharoensin, Chief Executive Officer of SEI Medical Public Company Limited, revealed that throughout the more than 30 years in the medical and scientific equipment industry, the company has focused on improving the quality of life and health of the population through innovation and cutting-edge technology. The funds raised from the fundraising will be used as working capital to expand the business, including increasing potential and competitiveness, such as working capital to purchase medical equipment and devices, to expand the consumables business, and joint investment projects with other companies engaged in the medical business, which may include specialized clinics or hospitals.

SEI has major shareholders after the IPO, namely Mr. Thira Punyacharoensin, holding 35.29 percent of shares, and Mr. Kan Punyacharoensin, holding 31.76 percent of shares. The company has a policy to pay dividends to shareholders at a rate of not less than 40 percent of net profit after tax and legal reserves.

Source: Thai News Agency